712 results about "Osteo arthritis" patented technology

A method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human knee joint and a device for delivering such signals to a patient's knee. An analytical model of the human knee is developed whereby the total tissue volume in the human knee may be determined for comparison to the total tissue volume of the diseased tissue in the animal model using electric field and current density histograms. The voltage and current output used in the animal model is scaled based on the ratio of the total tissue volume of the diseased tissue of the human to the total tissue volume of the diseased tissue in the animal model and the resulting field is applied to the diseased tissue of the human using at least two electrodes applied to the knee or a coil or solenoid placed around the knee. The voltage of the signal applied to the electrodes, coil or solenoid is varied based on the size of the knee joint; larger knee joints require larger voltages to generate the effective electric field.

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen.

The present invention provides compositions, combination of medicaments, and methods for the treatment of certain conditions such as arthritis, and in particular, reactive arthritis, osteoarthritis, and bursitis, among others.

Methods and devices for the regulation of matrix metalloproteinase gene expression in cartilage cells via the application of fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured articular cartilage. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased cartilage tissue that include generating specific and selective electric and electromagnetic signals that generate fields optimized for reduction of matrix metalloproteinase gene expression and exposing cartilage tissue to the fields generated by specific and selective signals so as to regulate matrix metalloproteinase gene expression in such cartilage tissue. The resulting methods and devices are useful for the targeted treatment of osteoarthritis, rheumatoid arthritis, cartilage injury, cartilage defects, and tumor metastasis.

The invention relates to a method for treating osteoarthritis by stem cells and a composition. Particularly, the invention relates to a cell treatment composition for treating osteoarthritis and cartilage defects. The composition includes mesenchyma stem cells, hyaluronic acid or pharmaceutical salt, sodium chloride and water. The invention also relates to a method for preparing the composition. The cell treatment composition has the excellent properties.

The anthranilic acid derivative or the salt thereof represented by the general formula

wherein R¹ and R² are hydrogen atom, or the like; R³ is a phenyl, cycloalkyl or bicyclic heterocyclic group which may be substituted, or the like; R⁴ is a phenyl, cycloalkyl or pyridyl group which may be substituted, or the like; X¹ is an alkylene or alkenylene group which may be substituted or a bond; X² is the general formula -X³-X⁴- or -X⁴-X³-, wherein X³ is a sulfur atom, an imino group or a bond, or the like; X⁴ means an alkylene or alkenylene group which may be substituted or a bond; is useful for a remedy such as rheumatoid arthritis, osteoarthritis and carcinoma, because it shows MMP-13 production inhibitory effect.

The present invention relates to a compound represented by the formula [I]

wherein X¹, X² and X³ are each an optionally substituted CH or a nitrogen atom, and any one of X¹, X² and X³ is a nitrogen atom, X⁴ is an optionally substituted CH, R¹ is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R² is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

The invention belongs to the field of pharmaceutical preparations and provides a Celecoxib nanosuspension and a preparation method thereof. Celecoxib is a novel non-steroidal anti-inflammatory drug, inhibits cyclooxygenase -2(COX-2) is through specificity, has anti-inflammatory and pain-easing effects and is clinically used for treating osteoarthritis and rheumatoid arthritis. However, the Celecoxib has very low solubility and in-vivo bioavailability. In order to increase the dissolution and the bioavailability of the drug, a high-speed shearing combined high-pressure homogenizing method is adopted to prepare the Celecoxib nanosuspension, the particle size and the polydispersion index PI are used as indicators for formulation technology optimization, a laser particle analyzer and a transmission electron microscope are adopted to study the particle size and form of the drug, the dissolution of the drug is evaluated through in-vitro dissolution experiments, and rat in-vivo pharmacokinetic study is conducted. Measurement results prove that the drug particle size of the nanosuspension is 50-500 nm, and the dissolution and the in-vivo bioavailability of the drug are increased obviously.

The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and/or prophylaxis of physiological and/or pathophysiological states in the triggering of which DDR2 is involved, in particular for use in the treatment and/or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.

The invention discloses a preparation method for a chitosan-based biomimetic membrane material with an asymmetric structure, and the preparation method comprises the following steps of dispersing chitosan into acetic acid aqueous solution, adding absolute methanol and acetic anhydride for reacting after the chitosan is completely dissolved, and then, centrifugally removing sediment; dropping in alkaline solidification liquid under stirring condition, and filtering to obtain chitosan microgel; adding the chitosan microgel in glycerin solution, injecting the solution in a mold, and standing and draining water, freeze-drying one part to obtain a chitosan-based porous sponge material, and drying the other part to obtain a chitosan-based dense membrane material; bonding the chitosan-based porous sponge material and the chitosan-based dense membrane material to obtain the chitosan-based biomimetic membrane material with asymmetric structure. The preparation method provided by the invention has the advantages that the preparation technology is simple, the prepared chitosan-based biomimetic membrane material has a porous sponge structure and a dense membrane material structure, the chitosan-based biomimetic membrane material is not curly when encountering water, guiding bone regeneration performance is good, and the chitosan-based biomimetic membrane material is degradable and controllable and can be widely used as a guided bone tissue regeneration membrane material in treatment of the fields such as dental implant, osteoarthritis, bone defect, and the like.

The invention relates to a pharmaceutical composition for the treatment of osteoarthritis, the composition of the invention consists of 5 to 10 weight parts of glucosamine hydrochloride, 5 to 10 weight parts of sodium chondroitin sulfate and 1 to 4 weight parts of sodium hyaluronate, and the needed oral formulation can be prepared by adopting the conventional preparation technology along with acceptable excipients in pharmacy. The pharmaceutical composition of the invention has the functions of prevention and treatment of osteoarthritis, so the invention can be used in the preparation of the drugs for the prevention and treatment of osteoarthritis and can also be used as the health care food which has the function of prevention of osteoarthritis.

The invention discloses a peptide (called BM23 peptide) which comprises 23 amino acids. The peptide derives from a BMP-2 amino acid sequence and is formed by mutation and modification. Compared with BMP-2, the peptide has remarkably improved stability and in-vivo effect duration, has activity for promoting differentiation of mesenchymal stem cells into cartilage cells and promoting cartilage cell proliferation, and can be used for repairing cartilage and/or treating osteoarthritis.

The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof. Moreover, the present invention is related to the treatment of rheumatoid arthritis, oesteoarthritis, ankylosing spondylitis, pain, primary dysmenorrhoea, acute tendinitis, bursitis and acute gout.

Calcareous materials which are very purified residues of corallinaceae particulary Lithothamnium corallioides have unusual therapeutic properties including treatment of conditions created by failure of immune regulation, for example rheumatoid or osteo arthritis, osteoporosis and other conditions involving pH control. A method for purification is provided. Also provided are compositions of the residues together with fatty acids, glycerides, polyglycols and emulsifiers. Particularly advantageous are compositions of the residues and medium chain triglycerides.